JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB312480

Alexa Fluor® 568 Anti-IFITM1 抗体 [EPR22620-12]

Alexa Fluor® 568 Anti-IFITM1 antibody [EPR22620-12]

Be the first to review this product! Submit a review

|

(0 Publication)

Rabbit Recombinant Monoclonal IFITM1 antibody - conjugated to Alexa Fluor® 568.

別名を表示する

CD225, IFI17, IFITM1, Interferon-induced transmembrane protein 1, Dispanin subfamily A member 2a, Interferon-induced protein 17, Interferon-inducible protein 9-27, Leu-13 antigen, DSPA2a

関連する標識済み抗体及び組成の異なる製品 (10)

  • 578 PE

    PE Anti-IFITM1 antibody [EPR22620-12]

  • HRP

    HRP Anti-IFITM1 antibody [EPR22620-12]

  • 617 Alexa Fluor® 594

    Alexa Fluor® 594 Anti-IFITM1 antibody [EPR22620-12]

  • 519 Alexa Fluor® 488

    Alexa Fluor® 488 Anti-IFITM1 antibody [EPR22620-12]

  • 665 Alexa Fluor® 647

    Alexa Fluor® 647 Anti-IFITM1 antibody [EPR22620-12]

  • 565 Alexa Fluor® 555

    Alexa Fluor® 555 Anti-IFITM1 antibody [EPR22620-12]

  • Unconjugated

    Anti-IFITM1 antibody [EPR22620-12]

  • 660 APC

    APC Anti-IFITM1 antibody [EPR22620-12]

  • 775 Alexa Fluor® 750

    Alexa Fluor® 750 Anti-IFITM1 antibody [EPR22620-12]

  • Carrier free

    Anti-IFITM1 antibody [EPR22620-12] - BSA and Azide free

Key facts

宿主種

Rabbit

クローン性

Monoclonal

クローン番号

EPR22620-12

アイソタイプ

IgG

標識

Alexa Fluor® 568

励起波長/蛍光波長

Ex: 578nm, Em: 603nm

キャリアフリー

No

アプリケーション

Target Binding Affinity, Antibody Labelling

applications

免疫原

The exact immunogen used to generate this antibody is proprietary information.

style
left-column
style
left-column

製品の詳細

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

How are conjugated primary antibodies validated?
This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling.
For suitable applications and species reactivity, please refer to the unconjugated version of this clone.

style
left-column

出荷温度及び保存条件

製品の状態
Liquid
精製方法
Affinity purification Protein A
バッファー組成
pH: 7.4 Preservative: 0.02% Sodium azide Constituents: 68% PBS, 30% Glycerol (glycerin, glycerine), 1% BSA
出荷温度
Blue Ice
短期保存期間
1-2 weeks
短期保存温度
+4°C
長期保存温度
-20°C
分注に関する情報
Upon delivery aliquot
保管に関する情報
Avoid freeze / thaw cycle|Store in the dark
style
left-column

補足情報

This supplementary information is collated from multiple sources and compiled automatically.

IFITM1 also known as Interferon-Induced Transmembrane Protein 1 has a molecular weight of approximately 14 kDa. It is a transmembrane protein that plays an important role in host defense mechanisms. IFITM1 is expressed in various tissues including the respiratory tract gastrointestinal tract and the immune system where it serves in defending against pathogenic infections. The protein is usually found on the cell membrane and becomes highly expressed in response to interferon signaling.
Biological function summary

This protein inhibits viral entry by restricting the fusion of viral membranes with host cell membranes. IFITM1 does not function alone; it is part of the IFITM family which includes IFITM2 and IFITM3 each contributing to antiviral defense. The protein is strategically positioned to prevent the spread of viruses by blocking them from entering new cells which is important for managing viral propagation.

Pathways

IFITM1 engages the innate immune response pathway responding to viral infections by acting as a barrier to viral entry. It works alongside related proteins such as IFITM2 and IFITM3 within this pathway. IFITM1 is also part of the interferon pathway where its expression is upregulated in response to interferon signals. This relationship highlights its role in the immune response acting as a frontline protector against the invasion of viruses like influenza and others.

IFITM1 has a significant role in the context of viral infections and certain cancers. It is linked to resistance to viral infections such as influenza showing its importance in antiviral defense. In cancer aberrant expression of IFITM1 is observed in various types including breast and colorectal cancers impacting tumor progression and metastasis. The relationship of IFITM1 with interferon signaling highlights potential therapeutic targets where modulating its activity could influence disease outcomes.
style
left-column
style
left-column

製品プロトコール

For this product, it's our understanding that no specific protocols are required. You can visit:
style
left-column

ターゲットの情報

IFN-induced antiviral protein which inhibits the entry of viruses to the host cell cytoplasm, permitting endocytosis, but preventing subsequent viral fusion and release of viral contents into the cytosol. Active against multiple viruses, including influenza A virus, SARS coronaviruses (SARS-CoV and SARS-CoV-2), Marburg virus (MARV), Ebola virus (EBOV), Dengue virus (DNV), West Nile virus (WNV), human immunodeficiency virus type 1 (HIV-1) and hepatitis C virus (HCV) (PubMed : 26354436, PubMed : 33270927). Can inhibit : influenza virus hemagglutinin protein-mediated viral entry, MARV and EBOV GP1,2-mediated viral entry and SARS-CoV and SARS-CoV-2 S protein-mediated viral entry. Also implicated in cell adhesion and control of cell growth and migration (PubMed : 33270927). Inhibits SARS-CoV-2 S protein-mediated syncytia formation (PubMed : 33051876). Plays a key role in the antiproliferative action of IFN-gamma either by inhibiting the ERK activation or by arresting cell growth in G1 phase in a p53-dependent manner. Acts as a positive regulator of osteoblast differentiation. In hepatocytes, IFITM proteins act in a coordinated manner to restrict HCV infection by targeting the endocytosed HCV virion for lysosomal degradation (PubMed : 26354436). IFITM2 and IFITM3 display anti-HCV activity that may complement the anti-HCV activity of IFITM1 by inhibiting the late stages of HCV entry, possibly in a coordinated manner by trapping the virion in the endosomal pathway and targeting it for degradation at the lysosome (PubMed : 26354436).
See full target information IFITM1
style
left-column
style
left-column

Abcam product promise

当社は、高品質な試薬を通じてお客様の研究を力強くサポートすることをお約束いたします。ご使用いただく各段階で、常にお客様をサポートできる体制を整えております。万が一、製品が期待通りに機能しない場合は、「Abcam Product Promise」による当社保証制度に基づき、安心してご利用いただけます。
保証に関する詳細については利用規約をご確認ください。
style
left-column
style
right-column

関連製品

Select an associated product type
Alternative Version
Primary Antibodies

AB255273

Anti-IFITM1 antibody [EPR22620-12] - BSA and Azide free

primary-antibodies

ifitm1-antibody-epr22620-12-bsa-and-azide-free-ab255273

0

(0 reviews)

style
bg-slate-100

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com